Our insights into the molecular mechanisms of melflufen activity in TP53<sup>-/-</sup> myeloma support its clinical efficacy and application in the del(17p) and TP53<sup>-/-</sup> patient population.Trial registration NCT03151811, registration 2017-05-09. Here, TP53 is linked to plasma cell myeloma.